Charles River Laboratories International, Inc. reported impairment charges for the first quarter ended March 30, 2024. for the quarter, the company reported long-lived asset impairment charges of $5,432,000 against $10,460,000 a year ago.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
219 USD | -1.12% | -5.83% | -7.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.36% | 11.28B | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024